HR-8358-119
Referred to the Committee on Oversight and Government Reform, and in addition to the Committees on Energy and Commerce, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sponsored by Beth Van Duyne (R-TX)
What it does
This bill would reauthorize the Breast Cancer Research semipostal stamp, a special U.S. postage stamp sold at a price above its face value. The surcharge collected above the postage rate would continue to be directed to breast cancer research funding. The program has operated periodically since 1998 and requires congressional reauthorization to continue.
Who benefits
Breast cancer researchers and the institutions that employ them, who would receive continued federal funding. Breast cancer patients and those at risk — particularly women, who account for the vast majority of diagnoses — who may benefit from research advances. Nonprofit and academic medical centers conducting breast cancer studies. The U.S. Postal Service, which administers the stamp program and gains public engagement. Stamp collectors who value commemorative semipostal issues.
Who is hurt
There are no clearly identified groups who are directly harmed by this bill. Competing medical research causes — such as other cancers or chronic diseases — do not receive the same dedicated stamp-based funding mechanism, which may represent an indirect opportunity cost. Postal customers who prefer not to pay a surcharge must seek out standard stamps, a minor inconvenience. Administrative costs of running the program are borne by the Postal Service and federal agencies.
Supporters argue
Supporters argue that the Breast Cancer Research stamp has raised over $100 million for research since its original authorization in 1998, making it one of the most successful semipostal programs in U.S. history. They contend that reauthorization costs taxpayers nothing directly — funding comes entirely from voluntary stamp purchasers — while sustaining a proven, popular mechanism that has contributed to meaningful advances in detection and treatment.
Opponents argue
Opponents argue that federal research funding priorities should be set through the transparent congressional appropriations process rather than through a consumer purchasing mechanism that favors one disease over others. They contend that the stamp program creates an uneven funding landscape where research into equally serious conditions — such as lung cancer, which kills more Americans annually — lacks a comparable dedicated revenue stream, raising questions of equity in federal health research priorities.